HPV vaccines and cervical cancer

Annals of Oncology

Volumn 19, Issue SUPPL. 5, 2008, Pages

  Bosch, F X ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANTIBODY TITER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; LONG TERM CARE; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; SEXUAL BEHAVIOR; TREATMENT INDICATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; ALPHAPAPILLOMAVIRUS; ARTICLE; IMMUNOLOGY; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ALPHAPAPILLOMAVIRUS; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 49049109325     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn310     Document Type: Conference Paper

References (12)

1. International Agency for Research on Cancer. Cervix Cancer Screening IARC Handbooks of Cancer Prevention. Lyon: IARC 2005.
2. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255.
3. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
4. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943.
5. Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-2170.
6. Castellsague X, Diaz M, de Sanjose S et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98: 303-315.
7. Hildesheim A, Herrero R, Wacholder S et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 2007; 298: 743-753.
8. Centers for Disease Control and Prevention. Quadrivalent Human Papillomavirus Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2007; 56: RR2. http://www.cdc.gov/mmwR/preview/mmwrhtml/rr56e312a1.htm.
9. ECDC. Guidance for the introduction of HPV vaccines in European countries 2008.
10. Global Advisory Committee on Vaccine Safety (GACVS) 2007 http://www.who.int/vaccine_safety/en/.
11. Ferlay F, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5 Version 2 0. Lyon: IARC 2005.
12. Kane MA, Sherris J, Coursaget P et al. Chapter 15: HPV vaccine use in the developing world. Vaccine 2006; 24 (Suppl. 3): S132-S139.